Novel dietary interventions for reducing obesity-associated breast cancer
减少肥胖相关乳腺癌的新型饮食干预措施
基本信息
- 批准号:10544502
- 负责人:
- 金额:$ 61.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdherenceAdipocytesAdultAdverse effectsAffectAgeAntiestrogen TherapyAttentionAttenuatedBehavior TherapyBehavioralBiologicalBiological MarkersBody Weight decreasedBreast Cancer PatientBreast Cancer PreventionBreast Cancer Risk FactorBreast Cancer survivorCaloric RestrictionCancer ControlCellsCessation of lifeCharacteristicsClinicalClinical ResearchDataDevelopmentDietary InterventionDiseaseDisease susceptibilityEstrogen receptor positiveEstrogensExtracellular MatrixFaceFibroblastsFoundationsFutureGrowthHealthHealth BenefitHumanImmuneIncidenceIndividualInflammatoryIntermittent fastingInterventionIntervention StudiesIntervention TrialLeadLife StyleMalignant NeoplasmsMammary NeoplasmsMediatorMedical OncologyMenopausal StatusMetabolicMetabolic DiseasesMetabolic dysfunctionModalityModelingNeoplasm MetastasisNewly DiagnosedObesityOutcomeOverweightPatient-Focused OutcomesPatient-derived xenograft models of breast cancerPatientsPersonsPhasePlayPostmenopausePredispositionPremenopausePrognosisProtein SecretionQuality of lifeRandomizedResearch PersonnelResistance developmentRiskRoleScienceSpecific qualifier valueStromal CellsStructureThinnessTimeTime-restricted feedingTranslatingTumor PromotionTumor SubtypeWeightWomanWorkbreast cancer diagnosisbreast cancer progressioncancer riskcancer subtypescirculating biomarkersclinically relevantcommon treatmentdietaryefficacy trialepidemiology studyhormone therapyimprovedimproved outcomeinnovationinterdisciplinary collaborationintervention deliveryintervention refinementmalignant breast neoplasmmammarynovelnovel therapeutic interventionnutritionobesity treatmentpatient derived xenograft modelpatient populationpreclinical studytherapy outcometriple-negative invasive breast carcinomatumortumor microenvironmenttumor progressionweight loss intervention
项目摘要
PROJECT SUMMARY
Despite new treatment modalities, the incidence of breast cancer has remained steady in recent years with
>250,000 new diagnoses and >40,000 deaths annually in the US. Concurrently, the proportion of US women
with overweight or obesity continues to rise, and is approaching 70%. Obesity and metabolic disease (which
occurs in lean and obese women) increase breast cancer incidence and worsen patient outcomes in women of
all ages. Premenopausal women with obesity are at increased risk of triple negative (TN) breast cancer (lacking
any targetable factors). Postmenopausal women with obesity incur more estrogen receptor (ER) positive breast
cancer and are more likely to develop resistance to endocrine therapies. While estrogen is clearly an important
part of this relationship, two key observations suggest that there may be estrogen-independent mechanisms at
play: 1) obesity is accompanied by worse prognosis for estrogen-independent triple negative breast cancer; and
2) anti-estrogen therapies are less effective against ER+ breast tumors in women with obesity. Regardless of
tumor subtype and menopausal status, excess weight is associated with poor outcomes for breast cancer
patients. Weight loss is known to improve breast cancer outcomes, but most people cannot sustain the standard
dietary weight loss strategies and weight regain is common. Intermittent energy restriction (IER) is a novel dietary
weight loss strategy that may have more beneficial effects on metabolic health and on breast cancer risk and
tumor progression. The work in this proposal will employ preclinical, clinical, and interventional studies, to
examine a novel mechanism of obesity-associated tumor progression and the value and feasibility of innovative
dietary interventions for eliminating obesity’s adverse effects on breast cancer.
We have merged expertise in nutrition, obesity, and medical oncology to: 1) examine a novel role that cancer-
associated fibroblasts (CAFs) and the tumor microenvironment (TME) may be playing in obesity-associated
tumor progression; 2) investigate if the novel dietary weight loss strategy of IER can eliminate obesity-associated
tumor progression; and 3) perform an ORBIT Phase IIa proof-of-concept study examining the ability of an IER-
based weight loss intervention to reach meaningful clinical milestones in breast cancer patients afflicted with
overweight and obesity and refine the intervention for delivery in a future randomized efficacy trial.
If the objectives of this proposal are achieved, we will have:
* Advanced our understanding of the obesity – breast cancer relationship, with evidence of a novel role for
CAFs and the TME in obesity-associated tumor promotion for TN and ER+ breast cancer;
* Established the foundation for IER weight loss trials in breast cancer survivors, with data that will help us
adapt these strategies to the unique characteristics and needs of this patient population; and
* Identified novel circulating biomarkers of a pro-metastatic TME, which may help identify patients most
susceptible to metastatic disease.
项目摘要
尽管有新的治疗方式,近年来乳腺癌的发病率保持稳定,
在美国,每年有超过25万例新诊断和超过4万例死亡。与此同时,美国女性的比例
超重或肥胖的比例继续上升,接近70%。肥胖和代谢性疾病(
发生在瘦和肥胖女性)增加乳腺癌的发病率,并使
所有年龄段肥胖的绝经前妇女患三阴性(TN)乳腺癌的风险增加(缺乏
任何目标因素)。绝经后肥胖妇女雌激素受体(ER)阳性乳腺癌发生率
癌症,更有可能对内分泌疗法产生耐药性。虽然雌激素显然是一个重要的
作为这种关系的一部分,两个关键的观察结果表明,
发挥:1)肥胖伴随着雌激素非依赖性三阴性乳腺癌的预后较差;
2)抗雌激素疗法对肥胖妇女的ER+乳腺肿瘤的效果较差。无论
肿瘤亚型和绝经状态,超重与乳腺癌预后不良相关
患者众所周知,减肥可以改善乳腺癌的预后,但大多数人无法维持标准
饮食减肥策略和体重反弹是常见的。间歇性能量限制(IER)是一种新型的饮食
减肥策略可能对代谢健康和乳腺癌风险产生更有益的影响,
肿瘤进展。本提案中的工作将采用临床前、临床和干预性研究,
研究肥胖相关肿瘤进展的新机制,以及创新治疗的价值和可行性。
饮食干预以消除肥胖对乳腺癌的不利影响。
我们将营养、肥胖和肿瘤医学方面的专业知识结合在一起,以:1)研究癌症的新作用-
相关的成纤维细胞(CAFs)和肿瘤微环境(TME)可能在肥胖相关的
肿瘤进展; 2)研究IER的新饮食减肥策略是否可以消除肥胖相关的
肿瘤进展;和3)进行ORBIT IIa期概念验证研究,检查IER-
基于减肥干预,以达到有意义的乳腺癌患者的临床里程碑,
超重和肥胖,并在未来的随机疗效试验中改进干预措施。
如果这项建议的目标得以实现,我们将:
* 我们进一步了解肥胖与乳腺癌的关系,有证据表明,
CAF和TME在TN和ER+乳腺癌的肥胖相关肿瘤促进中的作用;
* 为乳腺癌幸存者的IER减肥试验奠定了基础,数据将帮助我们
使这些策略适应该患者人群的独特特征和需求;以及
* 确定了促转移性TME的新型循环生物标志物,这可能有助于最大限度地识别患者
易患转移性疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VICTORIA A CATENACCI其他文献
VICTORIA A CATENACCI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VICTORIA A CATENACCI', 18)}}的其他基金
Training the Next Generation of Innovative and Collaborative Patient-Oriented Researchers to Reduce Obesity and Improve Cardiometabolic Health
培训下一代创新和协作的以患者为中心的研究人员,以减少肥胖并改善心脏代谢健康
- 批准号:
10721553 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Novel dietary interventions for reducing obesity-associated breast cancer
减少肥胖相关乳腺癌的新型饮食干预措施
- 批准号:
10367368 - 财政年份:2022
- 资助金额:
$ 61.66万 - 项目类别:
Does When You Exercise Matter? A Randomized Trial Comparing the Effect of Morning versus Evening Aerobic Exercise on Weight Loss and Compensatory Behaviors
运动时间重要吗?
- 批准号:
10627954 - 财政年份:2021
- 资助金额:
$ 61.66万 - 项目类别:
Does When You Exercise Matter? A Randomized Trial Comparing the Effect of Morning versus Evening Aerobic Exercise on Weight Loss and Compensatory Behaviors
运动时间重要吗?
- 批准号:
10296553 - 财政年份:2021
- 资助金额:
$ 61.66万 - 项目类别:
Does When You Exercise Matter? A Randomized Trial Comparing the Effect of Morning versus Evening Aerobic Exercise on Weight Loss and Compensatory Behaviors
运动时间重要吗?
- 批准号:
10470288 - 财政年份:2021
- 资助金额:
$ 61.66万 - 项目类别:
Comparison of Weight Loss Induced by Intermittent Fasting Versus Daily Caloric Restriction in Individuals with Obesity: A 1-Year Randomized Trial
肥胖个体间歇性禁食与每日热量限制引起的体重减轻的比较:一年随机试验
- 批准号:
9381546 - 财政年份:2017
- 资助金额:
$ 61.66万 - 项目类别:
Comparison of Weight Loss Induced by Intermittent Fasting Versus Daily Caloric Restriction in Individuals with Obesity: A 1-Year Randomized Trial
肥胖个体间歇性禁食与每日热量限制引起的体重减轻的比较:一年随机试验
- 批准号:
9981732 - 财政年份:2017
- 资助金额:
$ 61.66万 - 项目类别:
Comparison of Weight Loss Induced by Intermittent Fasting Versus Daily Caloric Restriction in Individuals with Obesity: A 1-Year Randomized Trial
肥胖个体间歇性禁食与每日热量限制引起的体重减轻的比较:一年随机试验
- 批准号:
10187552 - 财政年份:2017
- 资助金额:
$ 61.66万 - 项目类别:
Optimal Timing of Exercise Initiation Within a Lifestyle Weight Loss Program
生活方式减肥计划中开始运动的最佳时机
- 批准号:
8921190 - 财政年份:2013
- 资助金额:
$ 61.66万 - 项目类别:
Optimal Timing of Exercise Initiation Within a Lifestyle Weight Loss Program
生活方式减肥计划中开始运动的最佳时机
- 批准号:
9336877 - 财政年份:2013
- 资助金额:
$ 61.66万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 61.66万 - 项目类别:
Fellowship Programs